Authors: Magdalena Bazalova-Carter, Ross I. Berbeco, James Day, Xinchen Deng, Chelsea Amanda Saffron Dunning, Dianne M. Ferguson, Matthew W. Jacobson, Toby Morris, Marios Myronakis, Jericho Daniel O'Connell, Fides Schwartz, Jainil Shah, Aaron Sodickson
Affiliation: Brigham and Womens Hospital, University of Massachsetts Lowell and Dana-Farber Cancer Institute Boston, Medical Physics Department, Medical School, University of Thessaly, Brigham and Women's Hospital, Harvard Medial School, Dana-Farber Cancer Institute, Department of Radiation Oncology, University of Washington, University of Victoria, Siemens Healthineers, Dana Farber/Brigham and Women's Cancer Center, Brigham and Women's Hospital
Abstract Preview: Purpose: While CT imaging has advanced with improved machine design, we propose further gains can be achieved by enhancing sensitivity to contrast agents. Current CT sensitivity is limited to 1% bismu...
Authors: Stephanie Bennett, Ross I. Berbeco, Guillaume Bort, Needa Brown, Lena Carmes, Sandrine Dufort, Michael John Lavelle, Geraldine Le Duc, Francois Lux, Toby Morris, Zeinaf Muradova, Andrea Protti, Olivier Tillement
Affiliation: University de Lyon, NH TherAGuIX, University of Massachsetts Lowell and Dana-Farber Cancer Institute Boston, Department of Radiation & Cellular Oncology, University of Chicago, University of Central Florida, Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, NH TherAguix, Universite de Lyon, Brigham and Women's Hospital, Dana-Farber Cancer Institute
Abstract Preview: Purpose: AGuIX is a theranostic Gd-based nanoparticle currently under phase-2 clinical testing where patients receive 2-3 doses at 1-week intervals prior to imaging and irradiation. AGuIX-Bi is a new ...
Authors: Stephanie Bennett, Ross I. Berbeco, Ning Jin, Sonal Josan, Justin Michael Sheetz, Atchar Sudhyadhom
Affiliation: Department of Radiation & Cellular Oncology, University of Chicago, University of Massachusetts - Lowell, Siemens Healthineers, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School,, Brigham and Women's Hospital
Abstract Preview: Purpose: AGuIX, a Gadolinium-based theranostic radiosensitizing nanoparticle, is currently under clinical evaluation in Europe and the US. Using patients from the double-blinded NanoBrainMets trial, u...